Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PARP inhibitors for ovarian cancer – room for improvement with HRD testing

Thomas Helleday • 30 Sep 2019
ESMO 2019
Gynecological Cancer Ovarian Cancer

Thomas Helleday, MD, PhD, Karolinska Institute, Stockholm, Sweden & University of Sheffield, Sheffield, UK, stresses the need to improve homologous recombination deficiency (HRD) testing to provide more effective treatment with PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Thomas Helleday

2:40
Targeting the DNA damage response
Thomas Helleday • 29 Sep 2019
1:47
Challenges in treating cancers of unknown primary (CUP)
Thomas Helleday • 29 Sep 2019
2:49
Immunotherapy priming with neo-antigens
Thomas Helleday • 1 Jun 2019
3:07
The DNA damaging revolution
Thomas Helleday • 1 Jun 2019

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals